Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIO-NEONAX: Neoadjuvant plus adjuvant vs adjuvant-only nab-paclitaxel plus gemcitabine in resectable pancreatic cancer
2013-005559-34Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of paclitaxel and gemcitabine in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by AIO-Studien. Primary endpoint: Disease-free survival rate at 18 months. Started Aug 2014; status: completed.
02
Drugs
paclitaxelgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2013-005559-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005559-34.